2023
Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers
Pittet L, Messina N, Orsini F, Moore C, Abruzzo V, Barry S, Bonnici R, Bonten M, Campbell J, Croda J, Dalcolmo M, Gardiner K, Gell G, Germano S, Gomes-Silva A, Goodall C, Gwee A, Jamieson T, Jardim B, Kollman T, Lacerda M, Lee K, Lucas M, Lynn D, Manning L, Marshall H, McDonald E, Munns C, Nicholson S, O’Connell A, de Oliveira R, Perlen S, Perrett K, Prat-Aymerich C, Richmond P, Rodriguez-Baño J, dos Santos G, da Silva P, Teo J, Villanueva P, Warris A, Wood N, Davidson A, Curtis N. Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers. New England Journal Of Medicine 2023, 388: 1582-1596. PMID: 37099341, PMCID: PMC10497190, DOI: 10.1056/nejmoa2212616.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicBCG VaccineCOVID-19COVID-19 VaccinesDouble-Blind MethodHealth PersonnelHumansSARS-CoV-2ConceptsBacille Calmette-GuerinModified intention-to-treat populationIntention-to-treat populationSevere COVID-19Placebo groupSymptomatic COVID-19Health care workersBCG-DenmarkPlacebo-controlled trialCare workersRisk of severe COVID-19Double-blindSaline placeboRisk of symptomatic COVID-19Severe acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Negative testRandomized trialsRespiratory syndrome coronavirus 2Hazard ratioPrimary outcomeBCG vaccinationTrial definitionSyndrome coronavirus 2Risk difference
2020
Primary Prophylaxis to Prevent Tuberculosis Infection in Prison Inmates: A Randomized, Double-Blind, Placebo-Controlled Trial.
Dias de Oliveira R, da Silva Santos A, Reis C, de Cássia Leite A, Correia Sacchi F, de Araujo R, Dos Santos P, Rolla V, Martinez L, Andrews J, Croda J. Primary Prophylaxis to Prevent Tuberculosis Infection in Prison Inmates: A Randomized, Double-Blind, Placebo-Controlled Trial. American Journal Of Tropical Medicine And Hygiene 2020, 103: 1466-1472. PMID: 32876010, PMCID: PMC7543866, DOI: 10.4269/ajtmh.20-0110.Peer-Reviewed Original ResearchConceptsQFT conversionTB infectionSecondary outcomesPlacebo-controlled trialQuantiFERON-TB GoldFuture clinical trialsPrimary prophylaxisMiddle-income countriesPrimary outcomeTuberculosis infectionIntervention armTuberculosis incidenceControl armTrial protocolClinical trialsElevated riskInterim analysisLatent infectionCutoff pointInfectionTrialsHigher cutoffSustained conversionInternational unitsLower ratesEffect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Borba M, Val F, Sampaio V, Alexandre M, Melo G, Brito M, Mourão M, Brito-Sousa J, Baía-da-Silva D, Guerra M, Hajjar L, Pinto R, Balieiro A, Pacheco A, Santos J, Naveca F, Xavier M, Siqueira A, Schwarzbold A, Croda J, Nogueira M, Romero G, Bassat Q, Fontes C, Albuquerque B, Daniel-Ribeiro C, Monteiro W, Lacerda M. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. JAMA Network Open 2020, 3: e208857. PMID: 32330277, DOI: 10.1001/jamanetworkopen.2020.8857.Peer-Reviewed Original ResearchConceptsHigh dosage groupSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionAcute respiratory syndrome coronavirus 2 infectionLow dosage groupSyndrome coronavirus 2 infectionCoronavirus 2 infectionChloroquine diphosphateDay 13COVID-19Phase IIb clinical trialNonsevere COVID-19Secondary end pointsSevere COVID-19High-dose groupSpecific antiviral therapyTertiary care facilityIIb clinical trialCoronavirus disease 2019More heart diseaseParticipants' clinical statusAdjunctive therapyAdult patientsIll patientsPrimary outcomeAntiviral therapy